Author:
Kalambokis Georgios N.,Christaki Maria,Tsiakas Ilias,Despotis Grigorios,Fillipas-Ntekouan Sempastien,Fotopoulos Andreas,Tsiouris Spyridon,Xourgia Xanthi,Lakkas Lampros,Pappas Konstantinos,Michalis Lampros K.,Sergianiti Fotini,Baltayiannis Gerasimos,Christodoulou Dimitrios,Koustousi Christina,Aggelis Nikolaos,Milionis Haralampos
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference30 articles.
1. Portal hypertension bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 Practice guidance by the American Association for the Study of Liver Diseases;Garcia-Tsao;Hepatology,2017
2. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicenter trial;Villanueva;Lancet,2019
3. Beta adrenergic blockade and decompensated cirrhosis;Reiberger;J Hepatol,2017
4. Carvedilol action is dependent on endogenous production of nitric oxide;Afonso;Am J Hypertens,2006
5. Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis;Ling;Mol Med Rep,2019
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献